Ray Therapeutics

Ray Therapeutics is a biotechnology company that is advancing optogenetic gene therapies for patients with blinding diseases. Its lead candidate, Ray-001, is being developed to treat retinitis pigmentosa, a degenerative retinal disease with significant unmet medical needs. The treatment utilizes an intravitreal approach, diffusing from the vitreous to the retina and primarily transducing RGCs.